Clinical trial readout dates for MBX Biosciences Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is January 2028.
| Phase 3 Canvuparatide Hypoparathyroidism · NCT07699471 | January 2028 Recruiting |
| Phase 2 400 µg of MBX 2109 once-weekly by subcutaneous injection Hypoparathyroidism · NCT06531941 | May 2028 Ongoing |
MBX Biosciences Inc. reported $483M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-09). Its net loss for that quarter was $62M; at that rate the cash would last about 8 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Reg FD Disclosure — often a data announcement | 2026-11-09 |